Market Overview

UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility

Share:
Related ALKS
Alkermes 'Taking A Pause,' Citi Says
UPDATE: Morgan Stanley Downgrades Alkermes As Good News Is Appreciated
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co. (Seeking Alpha)

Morgan Stanley initiated coverage on Alkermes (NASDAQ: ALKS) with an Equal-weight rating and a $21 price target.

Morgan Stanley commented, "We have high regard for management, and see pipeline drug 5461 (depression) as intriguing. But we are cautious on commercialization prospects for 9070 (schizophrenia), and believe the stock valuation appropriately discounts growth outlook … ALKS trades at EV/EBITDA of 21x F13E and 15x F16E (we are focused on F16 because key launches are expected by then). We project 8-yr CAGR (F13-F21E) revenue growth of 6% and EPS growth of 13%. Note ALKS's low tax rate (est. mid-teens long-term) helps justify above average EBITDA multiple."

Alkermes closed at $19.97 on Monday.

Latest Ratings for ALKS

DateFirmActionFromTo
Mar 2015CitigroupDowngradesBuyNeutral
Mar 2015Morgan StanleyDowngradesEqual-weightUnderweight
Mar 2015JefferiesMaintainsBuy

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...